Full Text View
Tabular View
Study Results
Related Studies
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
This study has been completed.
Study NCT00506077   Information provided by Merck

First Received on July 24, 2007.   Last Updated on February 10, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Paranoid Schizophrenia
Additional conditions recognized in this trial
Cognition Disorders
Schizophrenia
Schizophrenia, Paranoid
More general conditions related to this trial
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
MK0249
Comparator: Placebo (unspecified)
Sponsors listed in this trial
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services